# A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors

> **NCT05712356** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Lisata Therapeutics, Inc.** · enrollment: 67 (actual)

## Conditions studied

- Cholangiocarcinoma
- Gallbladder Cancer
- Gallbladder Carcinoma
- Intrahepatic Cholangiocarcinoma
- Extrahepatic Cholangiocarcinoma
- Bile Duct Cancer
- Gall Bladder Cancer
- Gall Bladder Carcinoma

## Interventions

- **DRUG:** certepetide
- **DRUG:** Durvalumab
- **DRUG:** Cisplatin
- **DRUG:** Gemcitabine
- **DRUG:** FOLFOX regimen
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05712356
- **Lead sponsor:** Lisata Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-08-24
- **Primary completion:** 2026-04-18
- **Final completion:** 2030-03
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2025-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05712356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05712356, "A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05712356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*